- Home
- SXTC vs SGHT Comparison
SXTC vs SGHT Comparison
Compare SXTC & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- SGHT
- Stock Information
- Founded
- SXTC 2005
- SGHT 2011
- Country
- SXTC China
- SGHT United States
- Employees
- SXTC N/A
- SGHT N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- SGHT Medical Specialities
- Sector
- SXTC Health Care
- SGHT Health Care
- Exchange
- SXTC Nasdaq
- SGHT Nasdaq
- Market Cap
- SXTC 184.5M
- SGHT 193.2M
- IPO Year
- SXTC 2019
- SGHT 2021
- Fundamental
- Price
- SXTC $1.35
- SGHT $7.23
- Analyst Decision
- SXTC
- SGHT Buy
- Analyst Count
- SXTC 0
- SGHT 8
- Target Price
- SXTC N/A
- SGHT $4.93
- AVG Volume (30 Days)
- SXTC 244.1K
- SGHT 213.3K
- Earning Date
- SXTC 01-01-0001
- SGHT 11-06-2025
- Dividend Yield
- SXTC N/A
- SGHT N/A
- EPS Growth
- SXTC N/A
- SGHT N/A
- EPS
- SXTC N/A
- SGHT N/A
- Revenue
- SXTC $1,740,907.00
- SGHT $76,052,000.00
- Revenue This Year
- SXTC N/A
- SGHT N/A
- Revenue Next Year
- SXTC N/A
- SGHT $12.04
- P/E Ratio
- SXTC N/A
- SGHT N/A
- Revenue Growth
- SXTC N/A
- SGHT N/A
- 52 Week Low
- SXTC $0.95
- SGHT $2.03
- 52 Week High
- SXTC $7.84
- SGHT $8.06
- Technical
- Relative Strength Index (RSI)
- SXTC 47.18
- SGHT 69.14
- Support Level
- SXTC $1.32
- SGHT $6.74
- Resistance Level
- SXTC $1.65
- SGHT $7.24
- Average True Range (ATR)
- SXTC 0.13
- SGHT 0.51
- MACD
- SXTC 0.00
- SGHT 0.03
- Stochastic Oscillator
- SXTC 12.77
- SGHT 75.00
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.